Cancer
Conditions
Keywords
Taxotere, Cisplatin, Carboplatin, Trametinib, GSK1120212, Tarceva, KRAS, Pemetrexed, MEK inhibitor, nab-Paclitaxel, Docetaxel, Alimta, Abraxane, Erlotinib
Brief summary
The purpose of this study is to determine what dose of GSK1120212 can be given safely in combination with at least one other drug that is already approved to treat cancer. This study will test the safety of up to 6 different GSK1120212 study treatment combinations (GSK1120212 plus either docetaxel, erlotinib, pemetrexed, pemetrexed + carboplatin, pemetrexed + cisplatin, or nab-paclitaxel). The doses identified in this study may be used in future trials to test whether the combination treatment is a safe and effective therapy for subjects with metastatic lung and/or pancreatic cancers.
Interventions
Investigational small molecule targeted therapy (MEK1/2 inhibitor)
DRUGDocetaxel
Chemotherapy
DRUGErlotinib
Small molecule targeted therapy (EGFR inhibitor)
DRUGPemetrexed
Chemotherapy
DRUGCarboplatin
Chemotherapy
DRUGnab-Paclitaxel
Chemotherapy
DRUGCisplatin
Chemotherapy
Sponsors
GlaxoSmithKline
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* The subject has a solid tumor. Expansion cohorts are limited to non-small cell lung cancer and/or pancreatic cancer with or without a KRAS mutation. * Tumor progression following at least one prior standard therapy, the subject refuses standard therapy, or no standard therapy exists. * The subject has a radiographically measurable tumor. * The subject is able to carry out daily life activities without difficulty. * The subject is able to swallow and retain oral medication. * The subject does not have significant side effects from previous anti-cancer treatment. * The subject has adequate organ and blood cell counts. * Sexually active subjects must use medically acceptable methods of contraception during the course of the study.
Exclusion criteria
* The subject has had major surgery or received certain types of cancer therapy within 2-3 weeks before starting the study. * The subject has a brain tumor. * Current severe, uncontrolled systemic disease. * History of clinically significant heart, lung, or eye/vision problems. * The subject has high blood pressure that is not well-controlled with medication. * The subject has a permanent pacemaker. * The subject is pregnant or breastfeeding. * Positive for Hepatitis B, Hepatitis C, or HIV.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To determine the safety, tolerability, and recommended phase II dosing regimen of each GSK1120212-based treatment combination | Duration of study (approximately 3 years) |
Secondary
| Measure | Time frame |
|---|---|
| To characterize population pharmacokinetic parameters | Duration of study (approximately 3 years) |
| To evaluate the anti-tumor activity as assessed by tumor response rate according to RECIST v1.1 | Duration of study (approximately 3 years) |
Countries
Canada, France, South Korea, United States
Outcome results
None listed